ASDERA is developing the first drug with the potential to change the course of multiple sclerosis.

There are currently no drugs with a lasting effect for people with multiple sclerosis. The ASDERA platform identified the mechanism underlying macrophages targeting myelin and a drug to prevent them from becoming activated. 

(... to be continued ...)